Journal of Stroke and Cerebrovascular Diseases · Jul 30, 2026

Hyperhomocysteinemia and the risk of silent brain infarcts: systematic review and meta-analysis

By Afia M, Abdelraheam A, Vallamchetla SK et al.

BACKGROUND AND PURPOSE: Previous studies have reported differences in homocysteine levels between patients with and without silent brain infarction. However, evidence comparing silent brain infarct rates by hyperhomocysteinemia status remains limited. We conducted a systematic review and meta-analysis comparing silent brain infarct rates in patients with hyperhomocysteinemia versus normal homocysteine levels. METHODS: A systematic literature search was conducted from inception to June 17, 2025. Eligible studies compared the rate of image-confirmed silent brain infarcts in patients with hyperhomocysteinemia versus those with normal homocysteine levels. The primary outcome was the rate of silent brain infarcts, and the secondary outcome was cognitive performance assessed by the Mini-Mental State Examination (MMSE). Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model, with heterogeneity assessed using I² statistics. Subgroup analyses were performed according to hyperhomocysteinemia cutoffs (>12 µmol/L and 9-12 µmol/L) as defined in the included studies. RESULTS: Four observational studies involving 2331 patients were included (mean age 58.0±6.4 years; 45.8% women). Of these, 1087 had hyperhomocysteinemia and 1244 had normal levels. The rate of silent brain infarcts was 23.4% (253/1087) in patients with hyperhomocysteinemia versus 22.8% (284/1244) in controls (OR 1.84; 95% CI 1.09-3.11; P = 0.02). The association was higher in studies using a >12 µmol/L cutoff (OR 3.08; 95% CI 1.85-5.11; P < 0.0001). MMSE scores were numerically lower in patients with hyperhomocysteinemia but did not differ significantly from controls (mean difference -1.55; 95% CI -3.60-0.50; P = 0.14). CONCLUSIONS: Hyperhomocysteinemia is associated with an increased risk of silent brain infarcts and numerically lower cognitive performance. Findings suggest that the association between homocysteine and silent brain infarction may be stronger at higher homocysteine levels. Prospective studies are needed to determine whether homocysteine is a modifiable therapeutic target for reducing silent infarcts and cognitive decline.

doi.org/10.1016/j.jstrokecerebrovasdis.2026.108712Open accessPubMed 42532456Populations

AgingResearch.News